Skip to main content
. Author manuscript; available in PMC: 2023 Apr 20.
Published in final edited form as: Med. 2023 Mar 8;4(4):233–244. doi: 10.1016/j.medj.2023.02.003

Table 2.

Ongoing clinical trials evaluating abscopal responses

Trial Tumor type Systemic therapy RT Phase Sequence of systemic therapy
NCT01976585 low-grade lymphoma intratumoral Flt3L and poly-ICLC low dose 1/2 –
NCT02768558 lung cancer sequential nivolumab, concurrent cisplatin + etoposide 60 Gy 3 concurrent followed by sequential
NCT03192059 cervical and uterine cancer pembrolizumab 8 Gy/3 fractions 2 concurrent
NCT02992912 multiple atezolizumab 45 Gy/3 fractions 2 concurrent
NCT04245514 stage III lung cancer neoadjuvant and adjuvant durvalumab, neoadjuvant cisplatin + docetaxel 20 × 2 Gy every day for 4 weeks, 5 × 5 Gy every day for 1 week, or 3 × 8 Gy every other day for 1 week 2 neoadjuvant followed by adjuvant
NCT03721341 multiple (4–10 lesions) palliative RT, chemotherapy, immunotherapy, hormone therapy, or observation SABR (20 Gy/1 fraction, 30 Gy/3 fractions, or 35 Gy/5 fractions) along with investigator-chosen therapy, including chemotherapy, immunotherapy, hormone therapy, and active surveillance 3 concurrent
NCT03137771 non-small cell lung cancer docetaxel, erlotinib, gemcitabine, pemetrexed ± pembrolizumab SBRT N/A sequential
NCT04785287 multiple BMS-986218 ± nivolumab SBRT induced RadScopal effect 1/2 concurrent
NCT05039632 multiple intratumoral NBTXR3 + ipilimumab + nivolumab abscopal versus RadScopal effect 1/2 sequential
NCT03480334 relapsed Hodgkin’s lymphoma nivolumab 20 Gy 2 concurrent
NCT04873440 multiple inhaled manganese conventional RT vs. SBRT 1/2 sequential
NCT04238169 advanced NSCLC toripalimab vs. bevacizumab + toripalimab SBRT 30–50 Gy/5 fractions (2–4 lesions) 2 concurrent
NCT03449238 breast cancer with brain metastases pembrolizumab SRS 1/2 concurrent
NCT03457948 NET and metastatic liver lesions pembrolizumab PRRT using 177Lu-DOTA0-Tyr3-octreotate vs. transarterial embolization vs. yttrium-90 microsphere radioembolization 2 concurrent

Poly-ICLC, polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose; Flt3L, FMS-like tyrosine kinase 3 ligand; SABR, stereotactic ablative radiotherapy; NET, neuroendocrine tumor; SBRT, stereotactic body radiation therapy; PRRT, peptide receptor radionuclide therapy; NSCLC, non-small cell lung cancer; SRS, stereotactic radiosurgery; RT, radiation therapy.